| Excerpt | Relevance | Reference |
|---|
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 7.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 3.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |